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Abstract
Background: Modular mega-endoprosthesis systems are used to bridge very large bone defects and have become
a widespread method in orthopaedic surgery for the treatment of tumours and revision arthroplasty. However, the
indications for the use of modular mega-endoprostheses must be carefully considered. Implanting modular
endoprostheses requires major, complication-prone surgery in which the limited salvage procedures should always
be borne in mind. The management of periprosthetic infection is particularly difficult and beset with problems.
Given this, the present study was designed to gauge the significance of periprosthetic infections in connection
with modular mega-implants in the lower extremities among our own patients.
Methods: Patients who had been fitted with modular endoprosthesis on a lower extremity at our department
between September 1994 and December 2011 were examined retrospectively. A total of 101 patients with 114
modular prostheses were identified. Comprising 30 men (29.7 %) and 71 women (70.3 %), their average age at the
time of surgery was 67 years (18–92 years).
Results: The average follow-up period was 27 months (5 months and 2 weeks to 14 years and 11 months) and the
drop-out rate was about 8.8 %. Altogether, there were 19 (17.7 %) endoprosthesis infections: 3 early infections and
16 late or delayed infections. The pathogen spectrum was dominated by coagulase-negative staphylococci (36 %)
and Staphylococcus aureus (16 %), including 26 % multi-resistant pathogens. Reinfection occurred in 37 % of cases
of infection. Tumours were followed by significantly fewer infections than the other indications. Infections were
twice as likely to occur after previous surgery.
Conclusion: In our findings modular endoprostheses (18 %) are much more susceptible to infection than primary
endoprostheses (0.5–2,5 %). Infection is the most common complication alongside the dislocation of proximal
femur endoprostheses. Consistent, radical surgery is essential – although even with an adequate treatment strategy,
the recurrence rate is very high. Unfortunately, the functional results are frequently unsatisfactory, with amputation
often being the last resort. Therefore, the indication for implantation must be carefully considered and discussed in
great detail, especially in the case of multimorbid patients with previous joint infections.
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Background
Ever since Austin Moore fitted the first large metallic
implant in a patient with a giant cell tumour of the
proximal femur back in 1940, ‘mega-endoprostheses’
have become an accepted way of bridging large defects
of long bones [1–3]. Early implants, which were made
individually in an expensive, time-consuming process
and whose intraoperative inflexibility was limited, have
now largely been replaced by modular endoprosthesis sys-
tems. Primarily designed for the treatment of tumours,
these systems are now used as standard in orthopaedic
surgery for both primary and revision arthroplasty. Al-
though the majority of experience has been obtained in
tumour surgery, in the meantime the indications for
mega-endoprostheses have substantially widened and
other major defects, especially in connection with the re-
placement of existing prostheses, can also be bridged
more successfully than with one-piece special implants. In
particular, modular mega-endoprostheses are an import-
ant option in the event of loose implants, periprosthetic
fractures with extensive osseous substance defects, peri-
prosthetic infections and pseudarthrosis (non-union) or
dislocation [4, 5]. As a broad market has developed for the
use of mega-endoprostheses in revision arthroplasty as a
result, almost all orthopaedic implant manufacturers now
offer modular and revision systems to treat extensive sub-
stance defects of the lower extremities which in some
cases can also be combined with the manufacturers’ pri-
mary implants [6].
With primary arthroplasty on the rise, cases of revision
arthroplasty are also set to increase [7]. Since modular
mega-endoprosthesis systems can be modified intraoper-
atively, they enable solutions even in complex cases
where previously only unsatisfactory resection arthro-
plasty or amputations were possible and are being in-
creasingly employed in revision arthroplasty [8–10].
However, the indications for the use of modular mega-
endoprostheses must be strictly verified [10]. Implanting
modular endoprostheses requires major, complication-
prone surgery in which the limited salvage procedures
should always be borne in mind. Due to numerous dif-
ferences from primary arthroplasty such as the implants’
larger surface area, greater access, the frequently longer
duration of surgery, higher blood loss and patients who
are often multi-morbid, fitting mega-endoprostheses is
associated with higher complication rates and should
only be carried out by medical centres with the appro-
priate expertise [4]. This is particularly so in cases of
periprosthetic infection with a lying mega-endoprosthesis,
a high percentage of which lead to ablative surgery or even
death [11].
Given this, the present study was designed to gauge the
significance of periprosthetic infections in connection with
modular mega-implants in the lower extremities among
our own patients. This will allow risk factors to be identi-
fied relating in particular to indications or the patient
population as well as problems compared to primary peri-
prosthetic infections. Another goal is to report on the as-
sessment of implant infections in modular systems in the
current medical literature.
Methods
To select the patient cohort, all the patients were retro-
spectively identified who had been fitted with a modular
endoprosthesis in the lower extremity at our hospital be-
tween September 1994 and December 2011. Patients’
data was collected based on their archived records and
electronic files in IS-H SAP (Siemens AG Healthcare
Sector, Erlangen, Germany) as well as radiological find-
ings and images from SIENET MagicWeb/ACOM (Sie-
mens AG Healthcare Sector, Erlangen, Germany).
From the patient population, a total of 101 patients with
114 implanted modular endoprostheses were identified.
The München-Lübeck™ modular endoprosthesis sys-
tem (AQ Implants, Ahrensburg, Germany) was used. It
was developed by Ascherl and Gradinger between 1992
and 1994, and first used in hospitals in 1994 [11, 12].
The system consists of extraosseous modules for the hip,
knee and bone shaft as well as intramedullary rods. The
individual components are attached by means of conical
clamping and additional screw locking. Gradual length
adjustment combined with the conical plug system allow
the intraoperative selection and combination of individ-
ual implant components as well as rotation, antetorsion
and curvature correction (Fig. 1) [10–12].
Statistical analysis was performed using the spread-
sheet software Microsoft Excel (Microsoft Corporation,
Redmond, USA). The t-test for two dependent samples
was used to calculate significance, the level of signifi-
cance being set at 5 % (α = 0.05).
The diagnosis of periprosthetic infection was provided
on the basis of international consensus for the diagnosis
of periprosthetic infection.
As reinfection or recurrence we defined a clinically
and microbiologically recurrence of local periprosthetic
joint infections according antibiotic-free period and the
absence of clinical symptoms for at least 6 weeks.
Results
The average follow-up period was about 27 months
(5 months and 2 weeks to 14 years and 11 months).
Altogether, 104 implants (91.2 %) fitted at our depart-
ment were considered for this study, the drop-out rate
being 8.8 %. The patient cohort comprised 30 men
(29.7 %) and 71 women (70.3 %). Their average age at
the time of surgery was 67 years (18–92 years), the aver-
age age of males being about 60 and of females about
70. Fifty-seven (50 %) of the implants had been fitted on
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the right side and 57 (50 %) on the left. In no cases was
bilateral implantation carried out. The average BMI was
about 27 ± 5 kg/m2 (16.9–43.8 kg/m2; N= 109).
Seven patients died within the first six months of non-
infection-related causes. (Pulmonary embolism, tumor
progression, etc.) These were not included in the further
evaluation.
The indications were tumour (45 cases/39.5 %), TEP
loosening (38/33.3 %), periprosthetic fracture (25/21.9 %),
primary fracture (19/16.7 %), condition after TEP removal
due to infection (11/9.6 %), pseudarthrosis (7/6.1 %) and
recurrent dislocation of the TEP (1/0.9 %) (N= 146 with
multiple indications). In 73 cases (64 %), previous opera-
tions had been carried out: primary THA implant (19
cases/26 %), THA replacement (15/20.5 %) and proximal
femur replacement (8/11 %) as well as primary implant-
ation of total knee arthroplasty (TKA) (12/16.4 %) and
TKA replacement (2/2.7 %). There were another 8 cases
(11 %) of osteosynthesis and 3 other operations (cement
filling for osteomyelitis in childhood, corrective osteotomy
and excochleation with filling).
Regarding localization, proximal femur replacement in
75 cases (65.8 %) was followed by distal femur replace-
ment (28 cases/24.6 %), proximal tibia (4/3.5 %), total
femur replacement (3/2.6 %) and diaphyseal replacement
(3/2.6 %).
Endoprosthesis infections occurred in 19 cases (17,7 %),
making it the second-most common complication after
dislocation (20 cases/18.4 %). They comprised 3 early in-
fections (within the first 6 weeks) and 16 late or delayed
infections (between 9 weeks and 6 years and 7 months
after implantation). Pathogens were identified in 14 cases;
in 5 cases infection was clinically and paraclinically evi-
dent although the pathogens were not identified. The
identified pathogens are listed in Table 1.
All infections were treated surgically. The only types
of treatment used were debridement with lavage (2
cases), spacers followed by two or more replacements of
the endoprosthesis (16 cases), removal without replace-
ment of the prosthesis/ resection arthroplasty (3 cases),
arthrodesis (3 cases) and amputation (2 cases). One
patient (female) died from the consequences of infection.
Seven of the 19 patients suffered reinfection of the
modular endoprosthesis, making a reinfection rate of
about 37 %.
There was no gender-based difference in infections (12
women and 7 men; insignificant (p = 0.464)).
Moreover, there were no significant differences be-
tween the ages of patients who did or did not develop
an infection: 62 years (33–87 years) with infection and
67 without (18–92 years); insignificant (p = 0.729). The
value of any findings would have been limited since ac-
cording to the Kolmogorov-Smirnov test (p = 0.013) the
age was not normally distributed.
Patients experiencing at least one infection had a BMI
that on average was 5 points higher than patients with
no infection (26 (19–37) patients with infection and 21
(14–44) patients without). However, this difference be-
tween the means is not significant either (p = 0.320)
since the distribution of BMI in the cohort was approxi-
mately normal (Kolmogorov-Smirnov test, p = 0.630).
Table 1 Absolute and percentage frequency distribution of
pathogen classes in the overall population (MDROs: multi-drug-
resistant organisms; M/OR CNS: methicillin (oxacillin) resistant
coagulase-negative staphylococci; MRSA: methicillin-resistant
Staphylococcus aureus)
Coagulase-negative staphylococci 7 36.6 %
Staphylococcus epidermitis 5 26.3 %
Staphylococcus capitis 1 5.3 %
Staphylococcus warnei 1 5.3 %
thereof M/OR CNS 4 21.0 %
Staphylococcus aureus 3 15.8 %
thereof MRSA 1 5.3 %
Bacillus subtilis 1 5.3 %
Enterococcus faecalis 1 5.3 %
Pseudomonas aeruginosa 1 5.3 %
Escherichia coli 1 5.3 %
overall MDROs 5 26.0 %
no microbial detection 5 26.0 %
Fig. 1 Different types of the modular system (By kind permission of AQ Implants, Ahrensburg, Germany)
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Patients with a tumour as the main indication for
the implant of a modular endoprosthesis suffered sig-
nificantly fewer infections than patients with other in-
dications such as loosening, fractures, pseudarthrosis,
etc. (tumours 8.9 % vs. 21.7 % other indications; t-
test, p = 0.072).
In 73 patients, operations had been carried out before-
hand on the relevant joint. After previous surgery, infec-
tions were about twice as likely to occur (previous
surgery 20.5 % vs. no previous surgery 9.8 %, insignifi-
cant (p = 0.138)). Further classifying patients by types of
previous operations would yield numbers of cases which
are too low for statistical reliability.
Proximal femur replacement accounted for the largest
share of all modular endoprostheses (65.8 %). Infections
in connection with proximal femur replacement did not
occur significantly more frequently than with other lo-
calizations (p = 0.427).
In the case of distal femur replacement, although in-
fections did not take place more often than with other
localizations (p = 0.119), the frequency of all complica-
tions considered together was somewhat higher than
with other localizations.
Discussion
Probably the biggest challenge when treating endoprosth-
esis complications is managing periprosthetic infections
[7]. Particularly with large revision endoprostheses and
thus also modular mega-endoprostheses, this area is of
enormous importance. The infection rate in this study’s
patient population was 17.7 %. Infection rates of between
4 % and 24 % are quoted in the literature, significantly
higher than those encountered with primary implantations
of the hip and knee (0.5–1.5 %) and also revision surgery
(5 %) [10, 13–17]. Table 2 lists the current literature deal-
ing with the occurrence of infections in connection with
mega-endoprostheses. The reasons for this higher number
of periprosthetic infections include the considerably larger
foreign surface than on other endoprostheses. This large
foreign surface as well as more extensive surgical wounds,
lengthy operations and high blood loss increase the
chance of infection [4]. Furthermore, the modular design
with many dead spaces, gaps and grooves filling up with
blood and wound fluid seems to be conducive to infec-
tions [7] (Fig. 2). The side effects of continuing onco-
logical treatment may also constitute risk factors for
infection [18]. For example, radiotherapy has been shown
Table 2 Percentage of infection frequency of modular mega-implants in the lower extremities in the literature
Author/ year System Number of
patients
Locations Follow-up time Infections Comments
Roberts et al. 1991[25] STANMORE™ 135 knee not specified 6.8 %
Unwin et al. 1996 [26] STANMORE™ 1001 hip, knee, femur shaft 46 months 24.6 %
Mascard et al. 1998 [27] GUEPAR™ 90 knee 4.3 years (1–22 years) 13 %
Ilyas et al. 2001 [28] HMR- System 48 knee 5.6 years (2–10 years) 14.6 %
Donati et al. 2001 [15] KMFTR-System 34 knee 10 years 4 %
Mittermayer et al. 2001 [16] KMFTR-System 100 hip, knee, femur shaft 127.5 months 9.7 % 51 patients died and
41 patients analysed
Ilyas et al. 2002 [14] HMR- System 15 knee 6.7 years (3–10 years) 13.3 %
Griffin et al. 2005 [29] several 99 hip, knee, femur shaft 6 years (3.2–158.9 months) 10.1 %
Heisel et al. 2006 [17] MUTARS 50 hip, knee, femur shaft 46 monts (2–7 years) 12 %
Gosheger et al. 2006 [13] MUTARS 250 hip, knee, femur shaft not specified 12 %
Gerdesmeyer et al. 2006 [30] MML-System 70 hip, knee, femur shaft 7 years +/− 28 months none drop-out 46 %
Gradinger and Gollwitzer 2006 [12] MML-System 89 hip, knee, femur shaft not specified 3.3 %
Hardes et al. 2009 [31] MUTARS 28 hip, knee not specified 7.1 % without tumor
Chandrasekar 2009 [32] STANMORE™ 100 hip 24.6 months (0–60 months) 4 %
Kinkel et al. 2010 [33] MUTARS 77 hip, knee, femur shaft not specified 11.7 % 60 % complications
von Salis-Soglio et al. 2010 [10] MML-System 572 hip, knee, femur shaft not specified 10.5 %
Ruggeri et al. 2010 [34] KMFTR, HMRS,
GMRS
28 complete femur 8 months (1 month −17 years) 7.1 %
Winkelmann et al. 2010 [35] MUTARS 41 hip, knee, femur shaft 45 months 19.5 %
Pala et al. 2015 [36] GMRS 247 knee 4 years (2–8 years) 9.3 %
Capanna et al. 2015 [37] several 278 hip, knee more than 2 years 8.3 %
Sevelda et al. 2015 [38] several 50 complete femur 57 months (1–280 months) 12 %
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to be a risk factor, although this has not been proven for
chemotherapy [19]. The connecting tubes used – add-
itional non-perfused foreign bodies – may also promote
and maintain infection [10].
Another major factor is the patient’s history regarding
previous infections and operations. It was shown in our
study that when tumours were the main diagnosis for
the implant of a modular endoprosthesis, this resulted in
significantly fewer infections than the other indications.
In particular, foregoing infections play an important role
in the recurrence of a periprosthetic infection [7].
Ascherl et al. report that a significantly higher rate of in-
fection is to be expected in connection with revisions
after periprosthetic infection compared to primarily
aseptic replacement involving mega-endoprostheses [7].
Ahrens et al. found that reinfection was suffered by 43 %
of patients who had recovered from infection [20]. This
was borne out by the high reinfection rate in our own
study, in which reinfection accounted for 7 of the 19 in-
fections (37 %). High priority must be attached to pre-
venting infection [4].
Infection must be correctly diagnosed and classi-
fied for appropriate therapy [21]. For infections of
mega-prostheses, the classification system devised by
Tsukayama et al. is recommended [7, 22]:
I. Positive culture of intraoperative samples with no
previous indication of infection
II. Early infection: Onset of symptoms within 1 month
III.Chronic infection: Symptoms after 1 month
IV.(Acute) Hematogenous infection (2 years after
surgery)
Using this system is logical since it forms the basis for
the therapeutic approach. Positive intraoperative detec-
tion of pathogens with no other clinical or paraclinical
evidence of infection (Tsukayama Type I) could in par-
ticular be legally problematical. In uncertain cases, an in-
fection could be either simple contamination or a
previously asymptomatic early infection. Therefore, tak-
ing multiple intraoperative samples (at least 5) is import-
ant: if at least 3 show the same pathogen, infection
seems likely and should be treated as such [7, 21]. An
unusual spectrum of pathogens (enterobacteria, etc.) is
unlikely to be contamination and should be critically ex-
amined. In these cases, taking more samples by puncture
is advisable [21]. In cases of doubt, taking a consistent
approach and treating such findings as an early infec-
tion always appears to be the preferable response, even
if this remains an individual decision taken on a case-
by-case basis.
In the event of early infection (Tsukayama Type II),
open surgical revision should always be performed; anti-
biotic treatment or arthroscopic flushing is not effective
by itself. The wound should be completely reopened and
multiple samples taken in all layers followed by consist-
ent debridement and lavage. The complete replacement
of all movable endoprosthesis elements (PE bearings,
heads, etc.) as well as of non-cemented, screwed or
jammed modules and any connecting tubes used is
Fig. 2 a Intraoperative situs with surgically treated complete femur replacement with multiple resulting grooves on the connection points (short
arrows) and deep screw connections in the shaft (long arrows) b Intraoperative situs in connection with infected proximal femur replacement
with inflammatory tissue in the screw holes (arrow) and on the head; c After debridement
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essential. In this regard, it is vital to make sure preopera-
tively that the existing implants are complete and to
check for possible alternatives (perhaps by consulting
the respective manufacturer). In addition, local and sys-
temic antibiosis should be used, ideally in connection
with known pathogen patterns. The possible adoption of
a serial approach must be decided on a case-by-case
basis, since the functional outcome deteriorates with
each further revision in conjunction with often limited
muscle and soft tissue (sufficient soft tissue coverage is
essential for infection control) [7]. Generally, however,
the focus should always be on consistently curing the
infection.
In chronic infection 4–6 weeks after implantation
(Tsukayama Type III), a different procedure is required
since the initial colonization of the implant and the pos-
sible formation of a biofilm must be assumed [21]. The
endoprosthesis cannot usually be preserved in such
cases. A one-stage replacement as in primary peripros-
thetic infection is often ineffective. Instead, in our view,
a multi-stage approach should always be taken involving
the complete removal of all implant parts, the radical re-
section of infected tissue with debridement and lavage,
and local and systemic antibiosis. Cement spacers,
provisional prostheses or external fixators and exten-
sions can be used for temporary stabilization depending
on the location and extent of the defect, although with
defects often being extensive, such interim treatment is
frequently complicated and functionally unsatisfactory
for the patient. Once again, a serial approach is often ne-
cessary. Once the infection has been cured, in ideal cases
reimplantation is possible (Fig. 3). However, even larger
defects often arise due to surgical debridement, requir-
ing extended modules. One possible solution is the use
of arthrodesis modules, especially in the knee area. Even
so, they often have to be longitudinally cemented in the
tibia and femur, and in addition to their limited func-
tional results, salvage procedures upon reinfection are
barely possible (Fig. 4). Stabilizing the fistula is usually
only briefly effective (if at all) due to the multi-cavity si-
tuses as well as the distal and proximal spread of infec-
tion (Fig. 5). In 3 cases, the endoprosthesis was removed
owing to a serious infection and resultant spacer arth-
rodesis, leading in 1 case to amputation and another
case eventually to death. The use of arthrodesis after the
infection of a modular endoprosthesis is therefore only
partly suitable as palliation to avoid amputation [7]. In
the event of infection, the salvage possibilities are limited
and extremely difficult. This underlines the risk and ser-
ious consequences of infection in connection with a
lying modular endoprosthesis. Alongside tumour pro-
gression, infection in connection with an implanted
modular endoprosthesis is one of the most common rea-
sons for the amputation of the affected limb [18].
According to the literature, ‘hematogenous’ early infec-
tions (Tsukayama Type IV) can in some cases with sud-
den fulminant symptoms also be treated in isolation
antiobiotically. However, this approach has never been
successful at our department and therefore appears inef-
fective in connection with large implants. Once again, as
with chronic infection, a surgical procedure (see above)
is advisable. In individual cases, a single attempt can be
made to preserve the implant as with early infection, but
should be discussed in great detail.
In some works, titanium implants [20] and silver-coated
implants [23] are reported to result in a lower rate of in-
fection than cobalt-chromium based alloys. The surface of
silver-coated endoprostheses has an anti-infective effect,
as already demonstrated in animal experiments [23] and
in vivo studies [24]. Silver’s pharmacological safety has
also been demonstrated, for although silver ions were re-
leased, no side effects were observed as a result [20, 24].
Moreover, stocking-shaped fabrics (e.g. polyethylene ter-
ephthalate) have been described which, when introduced
above the implants, are supposed to promote healing and
seroma formation [7]. However, this method cannot solve
the complex problems entirely.
Another significant problem is the expected pathogen
pattern. Our own work revealed a similar pathogen
spectrum as in primary endoprosthesis infections with the
predominance of Staphylococcus aureus and coagulase-
negative staphylococci (Table 1). Strikingly, about 25 % of
Fig. 3 a Anterior-posterior X-ray of infected femur replacement
(chronic infection); b After removal and with inserted cement spacer;
c After reimplantation of a proximal femur replacement
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the pathogens showed a multi-resistant antibiotic spectrum.
Back in 2010, Ascherl described the further progress of the
multi-resistant pathogens MRSA (methicillin-resistant
Staphylococcus aureus) and MRSE (methicillin-resist-
ant Staphylococcus epidermidis) in modular TEP in-
fections [7]. In particular due to the formation of
biofilms, the collection of colonies, and low vulner-
ability to sometimes only bacteriostatic drugs (linezo-
lid), an endoprosthesis-conserving approach in connection
with MDROs (multi-drug resistant organism) is only
successful in isolated cases and should not be
attempted. Parvizi reports a 40 % reinfection rate for
infections of conventional endoprostheses by multi-
resistant staphylococci, which means the rate in con-
nection with modular prostheses is probably much
higher. The treatment of MDROs is and remains the
main challenge in the management of endoprosthesis
infections.
Conclusion
The 18 % rate of infection of modular endoprostheses
(4–36 % in the literature) is significantly higher than that
of primary endoprostheses and the most frequent com-
plication alongside the dislocation of the proximal femur
replacement. Infection control is challenging due to lim-
ited salvage procedures, the high recurrence rates and
Fig. 4 [18 F]FDG PET/CT: a Maximum intensity projection (MIP) of [18 F]FDG-PET; b MIP of [18 F]FDG PET/CT fusion and c MIP of CT (bony
window): clearly increased glucose consumption along the medial side of the arthrodesis (arrows) and punctum maximum at the distal end with
extension into the soft tissue as evidence of a prosthesis infection
Fig. 5 Obese 45-year-old patient with chronic fistula of the left hip in connection with inserted proximal femur replacement after multiple futile
infection eradiation: a overview; b and c detailed views
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patients’ frequent multi-morbidity. For therapy, Tsukaya-
ma’s classification system should be applied, and a con-
sistent, radical surgical procedure is essential. Even with
an adequate treatment concept, the recurrence rate is
very high at 36–43 %. Unfortunately, unsatisfactory
functional results often result, with amputation fre-
quently being the last resort.
Therefore, indications for implantation must be care-
fully considered and critically discussed, especially regard-
ing multi-morbid patients with previous joint infections.
Limitations
The retrospective design, the inhomogeneity of the pa-
tient population, and the relatively short follow-up
period are limitations of the present study. However, this
applies to the majority of studies of infected modular
mega-endoprostheses.
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